{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06441643",
            "orgStudyIdInfo": {
                "id": "GLR305-E001"
            },
            "organization": {
                "fullName": "Alcon Research",
                "class": "INDUSTRY"
            },
            "briefTitle": "Next Generation Rocklatan",
            "officialTitle": "A Phase II, Prospective, Two-Stage, Double-Masked, Randomized, Multi-Center, Controlled, Dose-Response Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-17043 and PG043 (AR-17043/Latanoprost) Ophthalmic Solutions in Subjects With Elevated Intraocular Pressure",
            "therapeuticArea": [
                "Cardiovascular",
                "Ophthalmology"
            ],
            "study": "next-generation-rocklatan"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-05",
            "overallStatus": "NOT_YET_RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-09",
                "type": "ESTIMATED"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-11",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-11",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-05-29",
            "studyFirstSubmitQcDate": "2024-05-29",
            "studyFirstPostDateStruct": {
                "date": "2024-06-04",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-05-29",
            "lastUpdatePostDateStruct": {
                "date": "2024-06-04",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Alcon Research",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The purpose of this two-stage clinical trial is to assess the safety and hypotensive efficacy of AR-17043 and PG043 ophthalmic solutions in subjects with open-angle glaucoma (OAG) or ocular hypertension (OHT).",
            "detailedDescription": "During Stage 1, approximately 100 adult subjects with OAG or OHT will be randomized to 5 arms: 3 different concentrations of AR-17043, placebo comparator, or netarsudil 0.02% (Rhopressa\u00ae) for a treatment duration of 7 days.\n\nDuring Stage 2, approximately 350 adult subjects with OAG or OHT will be randomized to 5 arms: low and high concentrations of PG043 (AR-17043/latanoprost 0.005%), AR-17043 high concentration, latanoprost, or netarsudil 0.02%/latanoprost 0.005% (Rocklatan\u00ae) for a treatment duration of 28 days."
        },
        "conditionsModule": {
            "conditions": [
                "Open Angle Glaucoma",
                "Ocular Hypertension"
            ],
            "keywords": [
                "Glaucoma",
                "IOP"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "QUADRUPLE",
                    "whoMasked": [
                        "PARTICIPANT",
                        "CARE_PROVIDER",
                        "INVESTIGATOR",
                        "OUTCOMES_ASSESSOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 450,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "AR-17043 low concentration (Stage 1)",
                    "type": "EXPERIMENTAL",
                    "description": "AR-17043 Ophthalmic Solution, one drop in each eye in the morning on Day 1, followed by one drop in each eye in the evening on Days 2-7.",
                    "interventionNames": [
                        "Drug: AR-17043 Ophthalmic Solution"
                    ]
                },
                {
                    "label": "AR-17043 medium concentration (Stage 1)",
                    "type": "EXPERIMENTAL",
                    "description": "AR-17043 Ophthalmic Solution, one drop in each eye in the morning on Day 1, followed by one drop in each eye in the evening on Days 2-7.",
                    "interventionNames": [
                        "Drug: AR-17043 Ophthalmic Solution"
                    ]
                },
                {
                    "label": "AR-17043 high concentration (Stage 1)",
                    "type": "EXPERIMENTAL",
                    "description": "AR-17043 Ophthalmic Solution, one drop in each eye in the morning on Day 1, followed by one drop in each eye in the evening on Days 2-7.",
                    "interventionNames": [
                        "Drug: AR-17043 Ophthalmic Solution"
                    ]
                },
                {
                    "label": "AR-17043 vehicle (Stage 1)",
                    "type": "PLACEBO_COMPARATOR",
                    "description": "AR-17043 Vehicle, one drop in each eye in the morning on Day 1, followed by one drop in each eye in the evening on Days 2-7.",
                    "interventionNames": [
                        "Drug: AR-17043 Vehicle"
                    ]
                },
                {
                    "label": "Rhopressa (Stage 1)",
                    "type": "ACTIVE_COMPARATOR",
                    "description": "Netarsudil 0.02% Ophthalmic Solution, one drop in each eye in the morning on Day 1, followed by one drop in each eye in the evening on Days 2-7.",
                    "interventionNames": [
                        "Drug: Netarsudil 0.02% Ophthalmic Solution"
                    ]
                },
                {
                    "label": "PG043 low concentration (Stage 2)",
                    "type": "EXPERIMENTAL",
                    "description": "PG043 Ophthalmic Solution, one drop in each eye in the evening on Days 1-28.",
                    "interventionNames": [
                        "Drug: PG043 Ophthalmic Solution"
                    ]
                },
                {
                    "label": "PG043 high concentration (Stage 2)",
                    "type": "EXPERIMENTAL",
                    "description": "PG043 Ophthalmic Solution, one drop in each eye in the evening on Days 1-28.",
                    "interventionNames": [
                        "Drug: PG043 Ophthalmic Solution"
                    ]
                },
                {
                    "label": "AR-17043 high concentration (Stage 2)",
                    "type": "ACTIVE_COMPARATOR",
                    "description": "AR-17043 Ophthalmic Solution, one drop in each eye in the evening on Days 1-28.",
                    "interventionNames": [
                        "Drug: AR-17043 Ophthalmic Solution"
                    ]
                },
                {
                    "label": "Latanoprost (Stage 2)",
                    "type": "ACTIVE_COMPARATOR",
                    "description": "Latanoprost 0.005% Ophthalmic Solution, one drop in each eye in the evening on Days 1-28.",
                    "interventionNames": [
                        "Drug: Latanoprost 0.005% Ophthalmic Solution"
                    ]
                },
                {
                    "label": "Rocklatan (Stage 2)",
                    "type": "ACTIVE_COMPARATOR",
                    "description": "Netarsudil 0.02%/Latanoprost 0.005% Ophthalmic Solution, one drop in each eye in the evening on Days 1-28.",
                    "interventionNames": [
                        "Drug: Netarsudil 0.02%/Latanoprost 0.005% Ophthalmic Solution"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "AR-17043 Ophthalmic Solution",
                    "description": "Investigational monotherapy supplied in three concentration levels: low, medium, high",
                    "armGroupLabels": [
                        "AR-17043 high concentration (Stage 1)",
                        "AR-17043 high concentration (Stage 2)",
                        "AR-17043 low concentration (Stage 1)",
                        "AR-17043 medium concentration (Stage 1)"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "PG043 Ophthalmic Solution",
                    "description": "Investigational fixed dose combination supplied in two concentration levels: low and high",
                    "armGroupLabels": [
                        "PG043 high concentration (Stage 2)",
                        "PG043 low concentration (Stage 2)"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Latanoprost 0.005% Ophthalmic Solution",
                    "description": "Marketed monotherapy",
                    "armGroupLabels": [
                        "Latanoprost (Stage 2)"
                    ],
                    "otherNames": [
                        "Latanoprost"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Netarsudil 0.02% Ophthalmic Solution",
                    "description": "Marketed monotherapy",
                    "armGroupLabels": [
                        "Rhopressa (Stage 1)"
                    ],
                    "otherNames": [
                        "Rhopressa\u00ae"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Netarsudil 0.02%/Latanoprost 0.005% Ophthalmic Solution",
                    "description": "Marketed fixed dose combination",
                    "armGroupLabels": [
                        "Rocklatan (Stage 2)"
                    ],
                    "otherNames": [
                        "Rocklatan\u00ae"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "AR-17043 Vehicle",
                    "description": "Placebo comparator",
                    "armGroupLabels": [
                        "AR-17043 vehicle (Stage 1)"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Mean diurnal IOP at Day 8 (Stage 1)",
                    "description": "Intraocular pressure (IOP) will be measured with a Goldmann tonometer. Diurnal IOP will be calculated as the average of the four measurements.",
                    "timeFrame": "Day 8 (8:00, 10:00, 12:00, 16:00)"
                },
                {
                    "measure": "Mean diurnal IOP at Day 29 (Stage 2)",
                    "description": "Intraocular pressure (IOP) will be measured with a Goldmann tonometer. Diurnal IOP will be calculated as the average of the three measurements.",
                    "timeFrame": "Day 29 (8:00, 10:00, 16:00)"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Mean IOP at each post-treatment timepoint (Stage 1)",
                    "description": "Intraocular pressure (IOP) will be measured with a Goldmann tonometer at each post-treatment timepoint.",
                    "timeFrame": "Day 1 (8:00, 10:00, 12:00), Day 8 (8:00, 10:00, 12:00, 16:00)"
                },
                {
                    "measure": "Mean change from the diurnally adjusted baseline IOP at each post-treatment timepoint (Stage 1)",
                    "description": "Intraocular pressure (IOP) will be measured with a Goldmann tonometer at each post-treatment timepoint and compared to the time-relevant (corresponding) baseline measurement. Baseline is defined as the last visit prior to initiation of treatment.",
                    "timeFrame": "Baseline (8:00, 10:00, 12:00, 16:00), Day 1 (8:00, 10:00, 12:00), Day 8 (8:00, 10:00, 12:00, 16:00)"
                },
                {
                    "measure": "Mean percent change from diurnally adjusted baseline IOP at each post-treatment timepoint (Stage 1)",
                    "description": "Intraocular pressure (IOP) will be measured with a Goldmann tonometer at each post-treatment timepoint and compared to the time-relevant (corresponding) baseline measurement. Baseline is defined as the last visit prior to initiation of treatment.",
                    "timeFrame": "Baseline (8:00, 10:00, 12:00, 16:00), Day 1 (8:00, 10:00, 12:00), Day 8 (8:00, 10:00, 12:00, 16:00)"
                },
                {
                    "measure": "Mean change from baseline mean diurnal IOP at each post-treatment timepoint (Stage 1)",
                    "description": "Intraocular pressure (IOP) will be measured with a Goldmann tonometer. The baseline mean diurnal IOP will be calculated as the average of the four baseline measurements. Baseline is defined as the last visit prior to initiation of treatment.",
                    "timeFrame": "Baseline (8:00, 10:00, 12:00, 16:00), Day 1 (8:00, 10:00, 12:00), Day 8 (8:00, 10:00, 12:00, 16:00)"
                },
                {
                    "measure": "Mean percent change from baseline mean diurnal IOP at each post-treatment timepoint (Stage 1)",
                    "description": "Intraocular pressure (IOP) will be measured with a Goldmann tonometer. The baseline mean diurnal IOP will be calculated as the average of the four baseline measurements. Baseline is defined as the last visit prior to initiation of treatment.",
                    "timeFrame": "Baseline (8:00, 10:00, 12:00, 16:00); Day 1 (8:00, 10:00, 12:00), Day 8 (8:00, 10:00, 12:00, 16:00)"
                },
                {
                    "measure": "Mean IOP at each post-treatment timepoint (Stage 2)",
                    "description": "Intraocular pressure (IOP) will be measured with a Goldmann tonometer at each post-treatment timepoint.",
                    "timeFrame": "Day 8 (8:00, 10:00, 16:00); Day 15 (8:00, 10:00, 16:00); Day 29 (8:00, 10:00, 16:00)"
                },
                {
                    "measure": "Mean change from the diurnally adjusted baseline IOP at each post-treatment timepoint (Stage 2)",
                    "description": "Intraocular pressure (IOP) will be measured with a Goldmann tonometer at each post-treatment timepoint and compared to the time-relevant (corresponding) baseline measurement. Baseline is defined as the last visit prior to initiation of treatment.",
                    "timeFrame": "Baseline (8:00, 10:00, 16:00); Day 8 (8:00, 10:00, 16:00); Day 15 (8:00, 10:00, 16:00); Day 29 (8:00, 10:00, 16:00)"
                },
                {
                    "measure": "Mean percent change from diurnally adjusted baseline IOP at each post-treatment timepoint (Stage 2)",
                    "description": "Intraocular pressure (IOP) will be measured with a Goldmann tonometer at each post-treatment timepoint and compared to the time-relevant (corresponding) baseline measurement. Baseline is defined as the last visit prior to initiation of treatment.",
                    "timeFrame": "Baseline (8:00, 10:00, 16:00); Day 8 (8:00, 10:00, 16:00); Day 15 (8:00, 10:00, 16:00); Day 29 (8:00, 10:00, 16:00)"
                },
                {
                    "measure": "Mean change from baseline mean diurnal IOP at each post-treatment timepoint (Stage 2)",
                    "description": "Intraocular pressure (IOP) will be measured with a Goldmann tonometer. The baseline mean diurnal IOP will be calculated as the average of the three baseline measurements. Baseline is defined as the last visit prior to initiation of treatment.",
                    "timeFrame": "Baseline (8:00, 10:00, 16:00); Day 8 (8:00, 10:00, 16:00); Day 15 (8:00, 10:00, 16:00); Day 29 (8:00, 10:00, 16:00)"
                },
                {
                    "measure": "Mean percent change from baseline mean diurnal IOP at each post-treatment timepoint (Stage 2)",
                    "description": "Intraocular pressure (IOP) will be measured with a Goldmann tonometer. The baseline mean diurnal IOP will be calculated as the average of the three baseline measurements. Baseline is defined as the last visit prior to initiation of treatment.",
                    "timeFrame": "Baseline (8:00, 10:00, 16:00); Day 8 (8:00, 10:00, 16:00); Day 15 (8:00, 10:00, 16:00); Day 29 (8:00, 10:00, 16:00)"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Stage 1 Key Inclusion Criteria;\n\n* Diagnosis of OAG or OHT in both eyes.\n* High unmedicated IOP measurements in the study eye as specified in the protocol.\n* Corrected visual acuity equal to or better than +1.0 logMAR (Snellen equivalent equal to or better than 20/200) in the study eye.\n* Other protocol-specified inclusion criteria may apply.\n\nStage 2 Key Inclusion Criteria:\n\n* Diagnosis of OAG or OHT in both eyes.\n* High unmedicated IOP measurements in the study eye as specified in the protocol.\n* Corrected visual acuity equal to or better than +0.7 logMAR (Snellen equivalent equal to or better than 20/100) in the study eye.\n* Other protocol-specified inclusion criteria may apply.\n\nStage 1 and Stage 2 Key Exclusion Criteria:\n\n* Current use of more than 2 ocular hypotensive medications within 30 days (either eye).\n* Intraocular pressure greater than 36 millimeters mercury (mmHg) at Screening.\n* Glaucoma other than OAG.\n* Previous glaucoma surgery.\n* Any abnormality preventing reliable measurements.\n* Unable to demonstrate proper eyedrop instillation.\n* Other protocol-specified exclusion criteria may apply.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Alcon Call Center",
                    "role": "CONTACT",
                    "phone": "1-888-451-3937",
                    "email": "alcon.medinfo@alcon.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Clinical Trial Lead, Pharma",
                    "affiliation": "Alcon Research, LLC",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "United Medical Research Institute",
                    "city": "Inglewood",
                    "state": "California",
                    "zip": "90301",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 33.96168,
                        "lon": -118.35313
                    }
                },
                {
                    "facility": "Eye Research Foundation",
                    "city": "Newport Beach",
                    "state": "California",
                    "zip": "92663",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 33.61891,
                        "lon": -117.92895
                    }
                },
                {
                    "facility": "Eye Center of Northern Colorado, PC",
                    "city": "Fort Collins",
                    "state": "Colorado",
                    "zip": "80528",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.58526,
                        "lon": -105.08442
                    }
                },
                {
                    "facility": "Coastal Research Associates",
                    "city": "Roswell",
                    "state": "Georgia",
                    "zip": "30076",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 34.02316,
                        "lon": -84.36159
                    }
                },
                {
                    "facility": "Scott & Christie and Associates, PC",
                    "city": "Cranberry Township",
                    "state": "Pennsylvania",
                    "zip": "16066",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.68496,
                        "lon": -80.10714
                    }
                },
                {
                    "facility": "University Eye Specialists",
                    "city": "Maryville",
                    "state": "Tennessee",
                    "zip": "37803",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 35.75647,
                        "lon": -83.97046
                    }
                },
                {
                    "facility": "Piedmont Eye Center",
                    "city": "Lynchburg",
                    "state": "Virginia",
                    "zip": "24502",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 37.41375,
                        "lon": -79.14225
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000005901",
                    "term": "Glaucoma"
                },
                {
                    "id": "D000005902",
                    "term": "Glaucoma, Open-Angle"
                },
                {
                    "id": "D000009798",
                    "term": "Ocular Hypertension"
                }
            ],
            "ancestors": [
                {
                    "id": "D000005128",
                    "term": "Eye Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M10024",
                    "name": "Hypertension",
                    "relevance": "LOW"
                },
                {
                    "id": "M9013",
                    "name": "Glaucoma",
                    "asFound": "Glaucoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M9014",
                    "name": "Glaucoma, Open-Angle",
                    "asFound": "Open Angle Glaucoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12731",
                    "name": "Ocular Hypertension",
                    "asFound": "Ocular Hypertension",
                    "relevance": "HIGH"
                },
                {
                    "id": "M8271",
                    "name": "Eye Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC14",
                    "name": "Heart and Blood Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC11",
                    "name": "Eye Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000019999",
                    "term": "Pharmaceutical Solutions"
                },
                {
                    "id": "D000077338",
                    "term": "Latanoprost"
                },
                {
                    "id": "D000009883",
                    "term": "Ophthalmic Solutions"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M21860",
                    "name": "Pharmaceutical Solutions",
                    "asFound": "Procedure",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4277",
                    "name": "Antihypertensive Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M12814",
                    "name": "Ophthalmic Solutions",
                    "asFound": "Anxiety",
                    "relevance": "HIGH"
                },
                {
                    "id": "M1775",
                    "name": "Latanoprost",
                    "asFound": "Basal",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "PhSol",
                    "name": "Pharmaceutical Solutions"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "AnAg",
                    "name": "Antihypertensive Agents"
                }
            ]
        }
    },
    "hasResults": false
}